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1  | INTRODUC TION
Pancreas transplantation is a definitive treatment for type 1 diabe‐
tes mellitus, having a 85% success rate of insulin independence at 
1 year.1
Currently, the number of potential recipients for a pancreas trans‐
plant exceeds the number of ideal donors. It is well established that 
successful solid organ transplant outcomes are dependent on careful 
donor and recipient selection; however, there is increasing pressure 
to meet the needs of patients on growing waiting lists. To overcome 
this shortfall, considerable attempts have been made to increase the 
donor pool. A recent meta‐analysis found that donors after circula‐
tory death (DCD) had comparable graft and recipient outcomes to 
donor after brain death (DBD) pancreas transplantation,2,3 but these 
are usually a highly selected cohort of often younger donors with 
minimal risk of a significant warm ischemic injury. Nevertheless, this 
suggests that pancreas transplants using carefully selected marginal 
donors may not have the morbidity often anticipated.
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Abstract
Substance	abuse	is	unfortunately	common	in	organ	donors.	Often,	these	organs	are	
declined for transplant, not only because of concerns around blood‐borne virus 
transmission but also because of perceived poor outcomes. In kidney transplantation, 
previous studies have demonstrated donor smoking status significantly impacts 
transplant outcome, but intravenous drug use or alcohol dependence does not. This 
study aims to clarify these issues in pancreas transplantation. Retrospective data on 
all UK solid organ pancreas transplants from 1994 to 2015 were obtained from the 
NHSBT	UK	Transplant	Registry.	The	impact	of	illicit	drug	misuse,	alcohol	abuse,	and	
smoking on graft and patient survival were analyzed using Kaplan‐Meier plots and a 
Cox	regression	model.	A	total	of	1175	of	the	2317	(49.5%)	donors	were	categorized	
as substance misusers. Univariate survival analysis revealed no significant impact of 
substance misuse on 10‐year graft or patient survival. Multivariate analysis con‐
firmed substance misuse was not associated with impaired graft or patient survival. 
A history of donor substance misuse does not negatively impact 10‐year graft or 
patient survival following pancreas transplantation. This is a large national registry 
analysis with long‐term follow‐up data and should therefore provide clinicians with 
reassurance when considering pancreas grafts from substance misuse donors.
K E Y W O R D S
alcoholism and substance abuse, donors and donation, donors and donation: extended  
criteria
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Donors who have misused substances, including alcohol, drugs 
(eg, cannabis, cocaine, heroin), and cigarette smoking are often con‐
sidered suboptimal due to the potential effects of these substances 
on the pancreas. These donors are usually young and otherwise 
ideal, but their organs are often turned down due to uncertainty 
surrounding the implications of their substance misuse on trans‐
plant outcomes. This is reflected in the high decline rate with 13% 
of otherwise acceptable organs rejected due to “donor history”.4
It is well established that the pancreas is particularly suscepti‐
ble to damage from alcohol. Long‐term alcohol abuse is the primary 
cause	of	chronic	pancreatitis,	accounting	for	approximately	70%‐80%	
of cases, and a major cause of acute pancreatitis.5 Clinicians have 
traditionally been wary of using organs from alcohol abuse donors 
as there is a perceived increased risk of reperfusion pancreatitis in 
the recipient. This complication is thought to be associated with in‐
creased patient morbidity and decreased pancreas graft survival.6
Donors who have engaged in illicit drug misuse, particularly intra‐
venous drug use, raise concerns regarding their blood‐borne virus sta‐
tus. Most donor‐to‐recipient disease transmissions are expected and 
as such pre‐emptive therapy and prophylaxis can be used to minimize 
the impact of transmission.7 However, despite screening, the transmis‐
sion of certain diseases (including HIV and HCV) may occur unexpect‐
edly.8 This remains a rare complication; however, when it does occur 
the ramifications can be severe with high adverse media interest.7
The association between smoking and vascular disease is well es‐
tablished. Vascular thrombosis is the main cause of early graft loss 
following pancreas transplantation, and theoretically, the endothe‐
lial activation associated with smoking may be transferred with the 
organ.	We	have	previously	demonstrated	that	recipient	smoking	does	
not negatively impact pancreas transplant outcomes9 but the impact 
of donor smoking on the graft has not been previously reported.
Most prior work into the effect of substance abuse on transplant 
outcomes have focused on the impact of recipient's smoking, illicit 
drug misuse, and alcohol dependency status, not the donor's history 
of substance misuse.10,11 In kidney transplantation, the outcomes 
following donor substance misuse have been better outlined. A large 
retrospective study found that in kidney transplants, a donor his‐
tory of cigarette smoking had a significant negative impact on both 
graft and recipient survival,12 whereas donor IV drug use and donor 
alcohol dependency were not found to have any significant adverse 
impact. As smoking,13 illicit drug misuse,14 and alcohol abuse15 are 
common within the general population, it is important to understand 
the potential impact this may confer on transplantation outcomes.
The aim of this study was to evaluate whether donor substance 
misuse has any effect on pancreas transplant outcomes, allowing op‐
timization of donor selection and providing clinicians with the confi‐
dence to scientifically assess the risk.
2  | MATERIAL S AND METHODS
The UK transplant registry is maintained by the National Health 
Service	 Blood	 and	 Transplant	 (NHSBT).	 Donor	 next	 of	 kin	 and	
recipients give informed consent for continuing data collection and 
subsequent analyses. There are eight centers in the UK that rou‐
tinely perform pancreas transplantation. Data on all UK solid organ 
pancreas	transplants	from	1984	to	2015	were	obtained	from	NHSBT	
UK transplant registry, n = 2618. Information on substance misuse 
was only available on those transplants performed from 1994 on‐
wards. Those patients for which there was no available information 
on substance misuse were removed from the analysis, resulting in a 
final	cohort	of	2317.	Substance	misuse	included	those	donors	with	a	
history of alcohol abuse, history of illicit drug misuse, or current/past 
cigarette	smoker	as	identified	and	recorded	by	Specialist	Nurses	in	
Organ	 Donation	 during	 the	 donor	 screening	 process.	 Sources	 of	
this information include the next of kin and the donor's GP medi‐
cal records. Data were also gathered on other donor variables in‐
cluded the following: age, sex, BMI, ethnic group, DBD/DCD, cause 
of death, warm ischemic time, cold ischemic time, smoking status, 
and alcohol history. The donor cause of death was coded as per 
NHSBT	core	donor	forms	and	for	the	purpose	of	this	analysis	was	
grouped into common codes, CVA, trauma, or other. CVA refers to 
cerebrovascular accident including ischemic stroke, intracerebral 
hemorrhage, and intracranial event unspecified. Recipient variables 
included the following: age, sex, BMI, ethnicity, sensitization, dialysis 
modality, previous transplant, mismatch grade, and immunosuppres‐
sion regimes. Information on recipient survival and death‐censored 
graft survival was extracted from the UK Transplant Registry.
To standardize terminology, we have grouped commonly used 
terms for different types of substance misuse under three headings. 
This is with an aim to be consistent with commonly used nomencla‐
ture	on	the	NHSBT	Core	Donor	Form.	Any	documented	history	of	
donor alcoholism, alcohol abuse, or alcohol dependence has been 
termed “Alcohol Abuse.” Any reported illicit drug misuse, including 
intravenous drug misuse, cannabis, cocaine, has been termed “drug 
misuse.” The term “smoker” incorporates any history of regular cig‐
arette or pipe smoking as recorded on the core donor forms. The 
umbrella term “substance misuser” incorporates all three of these 
categories.
2.1 | Statistical analysis
Follow‐up	analysis	of	 the	entire	cohort	was	submitted	to	NHSBT	by	
December 2015. All patients included had a minimum of 12 months fol‐
low‐up. Donor and recipient characteristics categorized by substance 
misuse	status	were	reported	as	percentages	or	mean	±	SD	where	ap‐
propriate. Univariate analysis was carried out using one‐way analysis 
of variance (ANOVA) with a Dunnett's post hoc multiple comparisons 
correction for continuous data. The donors with no history of sub‐
stance abuse were used as the control group for the Dunnett's test. 
Categorical data were analyzed using chi‐squared tests. Graft and pa‐
tient survival was censored at 10 years. Unadjusted graft and patient 
survival was calculated using Kaplan‐Meier (K‐M) plots and p‐values 
derived from the univariate log‐rank test. Given the heterogeneity of 
the recipients within the UK pancreas transplant registry, a sensitiv‐
ity analysis was performed to ensure validity of these findings when 
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applied to sub‐populations within the whole pancreas transplant co‐
hort,	 for	 example	 SPK	 only,	 DCD	 only,	 and	 re‐transplant	 recipients.	
Multivariate analysis was performed using a Cox proportional hazards 
regression model to analyze the combined effect of selected factors 
on all‐cause graft and patient survival. Log cumulative hazard plots 
were also analyzed and showed no evidence of non‐proportionality 
of hazards. All tests were two‐sided and p‐values of less than 0.05 
were deemed statistically significant. Analyses were performed using 
GraphPad	Prism	7.0	and	IBM	SPSS	Statistics	version	22.
3  | RESULTS
Of	the	2317	analyzed	transplants,	1175	were	categorized	as	substance	
misusers.	Within	this	cohort,	there	were	1129	(48.7%)	donors	with	a	
history	of	smoking,	163	(7%)	donors	with	a	history	of	alcohol	abuse,	
and	203	(8.7%)	donors	with	a	history	of	drug	abuse,	Table	1.	There	were	
327	donors	who	fell	into	more	than	one	category	of	substance	misuse.
3.1 | Clinical characteristics of donors with a 
history of substance misuse
Donors with a history of substance abuse represented a distinct pop‐
ulation when compared to the normal donor population. The majority 
of	donors	who	smoked	were	older	(36.3	±	11.7	vs	32.7	±	14.4	years,	
P < 0.001), whereas those donors with a history of drug abuse were 
more	likely	to	be	younger	(30.0	±	9.5	vs	32.7	±	14.4	years	P < 0.001) 
when compared with non‐substance‐misusing donors. There was a 
higher proportion of male donors with a history of alcohol abuse (M:F, 
65%:35%)	 and	 drug	 abuse	 (71.9%:28.1%),	P < 0.001. Those donors 
with a history of any substance misuse were also significantly more 
likely	 to	be	of	White,	Caucasian	ethnic	origin,	P = 0.02. There was 
no difference in the type of donation, DBD vs DCD. There was sig‐
nificant variation in donor's cause of death; the donors that smoked 
were more likely to die from a cerebrovascular accident (63.9% vs 
51.5%, P < 0.001) and donors with a history of drug abuse were more 
likely to die from “other” causes (36.9% vs 28.0%, P < 0.001) exam‐
ples include out of hospital cardiac arrest, meningitis, or suicide.
3.2 | Clinical characteristics of pancreas 
transplant recipients
With	 regard	 to	 the	 pancreas	 transplant	 recipient	 population,	
there were very few differences between the cohorts, Table 2. 
The groups were well matched for age, ethnicity, BMI, mismatch 
grade, dialysis status, type of pancreas transplant, warm and cold 
ischemic times. Recipients with their own history of substance mis‐
use (ie, smokers) were not any more likely to be allocated organs 
from donors with a history of substance abuse. Interestingly, men 
were significantly more likely to receive a pancreas graft from a 
donor with a history of drug or alcohol abuse than women, (alcohol 
abuse—59.5% vs 40.5%; drug abuse—61.6% vs 38.4%, P < 0.001).
3.3 | Univariate analysis of the impact of donor 
substance misuse on graft & patient survival
Data	on	graft	and	patient	survival	were	available	for	2073	recipients.	
Survival	analysis	using	Kaplan‐Meier	plots	revealed	a	donor	history	of	
TA B L E  1   Donor characteristics
Donor characteristic
No substance misuse, 
n = 1144 Donor smoking, n = 1129
Donor alcohol 
abuse, n = 163
Donor drug misuse, 
n = 203 P value
Age (y) 32.7	±	14.4 36.3	(±11.7)* 34.3 ± 13.4 30.0	±	9.5* <0.001*
Sex	(%)
Men 552 (48.2%) 566 (50.1%) 106 (65%) 146	(71.9%)
Women 592	(51.7%) 562 (49.8%) 57	(35%)* 57	(28.1%)* <0.001*
Ethnic group (%)
White 1040 (90.8%) 1056	(93.5%)* 153	(93.9%)* 185 (91.1%)
Other 104 (9.2%) 66 (5.8%) 10 (6.1%) 18 (8.9%) 0.025*
BMI (kg/m2) 23.3	±	3.7 23.8 ± 3.4 23.8 ± 3.6 23.4 ± 3.4 0.87
Donor type (%)
DBD 968 (84.5%) 983	(87.1%) 135 (82.8%) 164 (80.8%) 0.62
DCD 176	(15.4%) 146 (12.9%) 28	(17.2%) 39 (19.2%)
Donor cause of death (%)
CVA 589 (51.5%) 721	(63.9%)* 92 (56.4%) 93 (45.8%) <0.001*
Trauma 235 (20.5%) 174	(15.4%) 29	(17.8%) 35	(17.2%)
Other 320 (28.0%) 234	(20.7%) 43 (25.8%) 75	(36.9%)*
BMI, Body Mass Index; CVA, Cerebrovascular Accident; DBD, Donation after Brainstem Death; DCD, Donation after Circulatory Death.
Data	shown	as	mean	±	SD	or	percentage.
*,	highlights	significant	finding.
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substance misuse had no significant impact on 10‐year graft survival 
(GS)	or	patient	survival	 (PS),	Figure	1,	 (alcohol	abuse	GS	P	=	0.45;	PS	
P	=	0.65,	drug	misuse	GS	P	=	0.93;	PS	P	=	0.08	and	smoking	GS	P = 0.93; 
PS	P	=	0.51).	Survival	analysis	was	also	performed	examining	the	effect	
that	donors	with	a	history	of	multiple	substance	misuse	(n	=	327)	may	
have on outcomes. This again revealed there was no significant impact 
on graft survival (P	=	0.69)	or	PS	(P = 0.12). A sensitivity analysis was 
performed to evaluate the impact of donor substance misuse on dif‐
ferent sub‐categories within the pancreas transplant population, for 
example.	transplant	type	(SPK,	PAK,	PTA),	donor	type	(DCD	vs	DBD),	
and re‐transplants. This analysis revealed no effect of donor history of 
substance misuse on these sub‐populations (data not shown).
3.4 | Multivariate analysis of the impact of donor 
substance misuse on graft & patient survival
To understand the impact of donor substance misuse, within the con‐
text of the multiple confounding risk factors present in a large retro‐
spective registry analysis, a multivariate analysis was performed. This 
confirmed that any history of donor substance misuse was not associ‐
ated with impaired graft of patient survival in pancreas transplantation. 
Only traditional markers of poor outcome that is cold ischemic time 
(P < 0.0001, HR 1.001 95% CI 1.001, 1.002), increasing donor age 
(P = 0.02, HR 1.014 95% CI 1.002, 1.026), pancreas transplant alone 
(P	<	0.0001,	HR	2.71	95%	CI	1.69,4.3),	pancreas	after	kidney	(P<0.001, 
HR 2.24 95% CI 1.41, 3.55), and increasing recipient BMI (P = 0.03, HR 
1.042 95% CI 1.003, 1.082) were found to have a significant negative 
impact on graft survival, Table 3. Interestingly, a donor history of alcohol 
abuse was a significant covariate in the cox regression model; however, 
the HR was <1 indicating this is not associated with a negative effect on 
graft survival but a positive effect (P = 0.02, HR 0.54 95% CI 0.32, 0.92).
Recipient age (P	=	0.01,	HR	1.037	95%	CI	1.008,	1.067)	and	PTA	
graft (P = 0.006, HR 2.952 95% CI 1.36, 6.41) correlated with poor 
patient survival, Table 4.
3.5 | Postoperative complications
To evaluate the impact of donor substance misuse on the recipient's 
postoperative course, the rate of a number of common complications 
was compared between groups. These data were taken from the 3‐
month	follow‐up	report	submitted	to	NHSBT	by	transplant	coordina‐
tors. Follow‐up data were not routinely collected for the early cohort of 
TA B L E  2   Recipient characteristics
Recipient characteristic
No substance misuse, 
n = 1144 Donor smoking, n = 1129
Donor alcohol 
abuse, n = 163
Donor drug misuse, 
n = 203 P value
Age (y) 41.45 ± 8.4 41.9 ± 8.5 41.6 ± 8.4 41.3 ± 8.6 0.58
Sex	(%)
Men 517	(45.2%) 466 (41.3%) 97	(59.5%)* 125	(61.6%)*
Women 627	(54.8%) 663	(58.7%) 66 (40.5%) 78	(38.4%) <0.001*
Ethnic group (%)
White 1047	(91.4%) 1028 (91.1%) 146 (89.6%) 184 (90.6%)
Other 97	(8.5%) 101 (8.9%) 17	(10.4%) 19 (9.4%) 0.86
BMI (kg/m2) 24.5 ± 4.4 24.39 ± 4.3 24.5 ± 4.4 24.5 ± 3.8 0.94
Mismatch grade (%)
000 mismatch 11 (1%) 10 (0.9%) 1 (0.6%) 0
Favorable MM 66 (5.8%) 49 (4.3%) 10 (6.1%) 8 (3.9%)
Non‐favorable MM 1063 (92.8%) 1070(94.8%) 152 (93.3%) 195 (96.1%) 0.67
Dialysis status (%)
Hemodialysis 287	(25.1%) 316 (28%) 39 (23.9%) 61 (30.0%)
Peritoneal 227	(19.8%) 240 (21.3%) 40 (24.5%) 46	(22.7%)
Not on dialysis 540	(47.2%) 502 (44.5%) 74	(45.5%) 86 (42.4%) 0.39
Warm	ischemic	time	(min) 54.9 ± 108.5 49.4	±	78.2 50.8 ± 105.2 38.2	±	17.3 0.31
Cold ischemic time (min) 747.9	±	321.3 758.8	±	427.5 762.4	±	653.3 755.25	±	436.9 0.95
Type of transplant (%)
PAK 111	(9.7%) 108 (9.6%) 14 (8.6%) 13 (6.4%)
PTA 95 (8.3%) 81	(7.2%) 14 (8.6%) 18 (8.9%)
SPK 938 (81.9%) 940 (83.3%) 135 (82.8%) 172	(84.7%) 0.71
Recipient smokers 128 (11.2%) 135 (11.4%) 19	(11.7%) 30 (14.8%) 0.36
BMI,	Body	Mass	Index;	PAK,	Pancreas	After	Kidney	transplant;	PTA,	Pancreas	Transplant	Alone;	SPK	Simultaneous	Kidney‐Pancreas	Transplant.
Data	shown	as	mean	±	SD	or	percentage.
*,	highlights	significant	finding.
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transplants (prior to 2006) so the overall figures for these complication 
rates are lower when compared with other reported series. However, 
interestingly, this revealed that recipients who received a graft from a 
donor with a history of smoking were significantly more likely to de‐
velop an anastomotic leak (34 in smoking cohort vs 15 in control co‐
hort, P = 0.006) than in grafts from non‐substance misuse donors.
4  | DISCUSSION
The findings of this paper demonstrate that a history of donor sub‐
stance misuse does not negatively impact on either 10‐year pan‐
creas graft or patient survival following pancreas transplantation. 
This is contrary to evidence in renal transplantation and the widely 
F I G U R E  1   Kaplan‐Meier survival plots demonstrate donor history of substance misuse does not impact 10‐y graft or patient survival
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held beliefs amongst transplant clinicians. This analysis therefore 
provides scope to widen the donor pool, utilizing marginal do‐
nors more readily. Clinicians should be confident in accepting a 
pancreas from a substance‐misusing donor if all other factors are 
favorable.
This retrospective data analysis is limited by a degree of selec‐
tion	bias.	With	previous	uncertainty,	as	to	outcomes	following	donor	
substance misuse it is likely that clinicians would only choose to 
transplant pancreas allografts from the healthiest of these donors, 
skewing our results in a positive light. Information regarding donor 
substance misuse is often provided by the donor's next of kin or 
friend. This collateral information may be inaccurate as family mem‐
bers may not be aware of all risk‐taking behaviors. Another difficulty 
associated with data capture in this circumstance is the confusing 
terminology. By using an inclusive, “broad‐brush” approach to incor‐
porate the entire spectrum of substance misuse and standardizing 
terminology to cover all variations, this may have resulted in a dilution 
of the actual effect size. For example, when comparing intravenous 
drug abuse versus casual cannabis misuse it might be assumed that 
one risk‐taking behavior is likely to have a more significant impact on 
a donor's health than the other. However, in our analysis these two 
situations were both coded as the same variable. Nonetheless, this 
approach was necessary to facilitate the analysis and is a standard 
methodology when dealing with large retrospective datasets. Also, 
the likelihood is, these two opposing difficulties with data collection 
have negated each other, and therefore, we feel these findings can 
be reflected as an accurate representation of the donor population. 
The sensitivity analysis also confirmed these findings were consistent 
when focussing on specific sub‐populations within the whole registry 
analysis.
This account is verified by the multivariate analysis which sug‐
gested that cold ischemic time, increasing donor age, increasing re‐
cipient BMI, PTA, and PAK pancreas grafts had a significant impact, 
with decreased graft survival. Increased recipient age and PTA grafts 
had a negative correlation with patient survival. These findings are 
well documented in previous literature.16
The primary concern many clinicians will have with accepting or‐
gans from substance misuse donors; particularly, IVDU donors are the 
TA B L E  3   Multivariate analysis of graft survival
Variable Hazards ratio 95.0% CI P value
Donor Type (DCD 
vs DBD)
0.953 (0.63,1.45) 0.82
Donor age 1.014* (1.00, 1.03) 0.02*
Donor BMI 0.982 (0.94, 1.03) 0.44
Donor history of 
alcohol abuse
0.541* (0.32, 0.92) 0.02*
Donor history of 
drug misuse
0.988 (0.56,	1.73) 0.96
Donor history of 
smoking
1.337 (0.98, 1.83) 0.07
Recipient age 0.993 (0.97,	1.01) 0.43
Recipient BMI 1.042* (1.00, 1.08) 0.03*
Sensitization	
pre‐transplant
1.003 (0.99, 1.01) 0.29
Hemodialysis 
pre‐transplant
1.160 (0.79,	1.71) 0.46
Peritoneal dialysis 
pre‐transplant
1.166 (0.76,	1.78) 0.48
Transplant 
type—Pancreas 
transplant alone
2.711 (1.68, 4.33) <0.0001*
Transplant 
type—Pancreas 
after kidney
2.236 (1.41, 3.55) 0.001*
Transplant year 1.064 (0.97,	1.16) 0.17
Warm	ischemic	
time
1.000 (0.99, 1.01) 0.298
Cold ischemic time 1.010* (1.01, 1.02) <0.0001*
BMI, Body Mass Index; DBD, Donation after Brainstem Death; DCD, 
Donation after Circulatory Death.
*,	highlights	significant	finding.
TA B L E  4   Multivariate analysis of patient survival
Variable Hazards ratio 95.0% CI P value
Donor type (DCD 
vs DBD)
0.794 (0.40, 1.59) 0.59
Donor age 1.006 (0.97,	1.03) 0.55
Donor BMI 0.988 (0.92,	1.07) 0.75
Donor history of 
alcohol abuse
0.573 (0.24, 1.40) 0.22
Donor history of 
drug misuse
1.353 (0.46, 3.96) 0.58
Donor history of 
smoking
1.261 (0.76,	2.09) 0.37
Recipient age 1.037* 1.01,	1.07) 0.01*
Recipient BMI 0.999 (0.94, 1.06) 0.97
Sensitization	
pre‐transplant
1.006 (0.99, 1.01) 0.16
Hemodialysis 
pre‐transplant
1.827 (0.99,	3.37) 0.06
Peritoneal dialysis 
pre‐transplant
1.289 (0.63, 2.64) 0.49
Transplant 
type—Pancreas 
transplant alone
2.952 (1.36, 6.41) 0.01*
Transplant 
type—Pancreas 
after kidney
0.731 (0.22, 2.40) 0.61
Transplant year 1.064 (0.97,	1.16) 0.17
Warm	ischemic	
time
1.001 (0.99, 1.01) 0.71
Cold ischemic time 1.001 (0.99, 1.00) 0.37
BMI, Body Mass Index; DBD, Donation after Brainstem Death; DCD, 
Donation after Circulatory Death.
*,	highlights	significant	finding.
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increased risk of viral transmission. A previous study published by one 
of our authors has investigated this aspect in significant detail using this 
same UK registry cohort of pancreas recipients but also including recip‐
ients of the other solid organs from the same donor. The study investi‐
gated outcomes from 1091 donors with a reported history of “increased 
risk‐taking behavior” for example current use or history of IVDU, current 
or previous imprisonment, men who have sex with men, sex in exchange 
for money or drugs, or a high‐risk sexual partner.17 This comprehensive 
study revealed there have been no reported incidences of viral trans‐
mission to pancreas graft recipients. In other solid organ transplants, 
there has been one case of unexpected transmission of HCV from a 
single donor affecting one liver and two kidney recipients infected. This 
particular donor had a history of recent IVDU and had negative HCV 
antibody titers at the time of donation. The liver recipient was known 
to be HCV positive prior to transplant; however, the predominant HCV 
genotype changed after transplant from genotype 1 to 3. There were no 
reported HIV, HBV, or HTLV transmissions from any of these “increased 
risk taking” donors.17 Currently, there are no nationwide guidelines on 
screening for seroconversion following transplantation in high‐risk do‐
nors and this is left to the individual clinician's discretion. The protocol 
in our center advocates testing for seroconversion if the donor was con‐
sidered high risk for blood‐borne virus transmission.
Historical data suggest that Hepatitis C has a negative impact on 
both patient and graft survival.18 Rapid advancements in direct‐act‐
ing antivirals (DAAs) means interferon‐free therapy with higher cure 
rates and less adverse side effects are now available. These have 
been used to enable kidney organ transplantation from HCV positive 
donors to HCV negative recipients who were treated with DAAs, 
preventing disease transmission.19 These affiliated lines of research 
could mean donor IVDU is no longer a barrier to transplantation.
Currently in the UK, blood‐borne virus screening of deceased 
donors relies on serology rather than nucleic acid testing (NAT). 
Uncertainty regarding the donor's serology may contribute to 
clinicians’ apprehension to utilize functionally good pancreata from 
donors with a history of drug misuse. NAT can significantly reduce 
the “window period” from infection to detection and decrease the 
risk of transmitting disease from a serologically negative donor.20 
However, NAT is costly and can be logistically challenging.21 A 
change in policy that advocates funding for routine NAT in high‐risk 
donors may increase the utilization of organs.22
Interestingly, the recipients who received a graft from a donor 
with a history of smoking were significantly more likely to go on to 
develop an anastomotic leak. Fortunately, this is did not impair long‐
term graft or patient survival. The underlying reason for more leaks 
may be explained by the well‐established effect that smoking has on 
wound healing and the microvasculature, resulting in the donor duo‐
denum being more susceptible to dehiscence. This is a well‐reported 
phenomenon in colorectal surgery.23
We	have	also	shown	that	donors	with	a	history	of	smoking	were	
likely to be older but this did not have a compounding effect on graft 
or	patient	survival.	When	adding	the	variables	into	the	multivariate	
model, donor age represented a significant hazard impairing graft 
survival, whereas smoking status did not. This demonstrates that the 
negative impact of donor age holds true in the model irrespective 
of donor smoking status and other potentially confounding variables. 
Equally, the nonsignificant impact of donor smoking status holds true 
when all other potentially confounding variables (donor age included) 
remain constant. The interaction term between donor age and smok‐
ing status was also nonsignificant revealing there is no compounding 
effect on graft survival when both of these variables are present.
The overall reported incidence of postoperative complications 
(Table 5) was significantly lower than other reported series. This 
likely represents a large amount of missing follow‐up data not being 
reported	back	to	NHSBT	post‐transplant.	However,	this	is	a	frequent	
problem when dealing with large retrospective databases24 and is 
TA B L E  5   Post‐op complications and length of stay
Complication at 3 mo 
follow‐up
No substance misuse, 
n = 1144
Donor smoking, 
n = 1129
Donor alcohol abuse, 
n = 163
Donor drug abuse, 
n = 203 P value
Median length of stay (d) 17	(0‐742) 17	(0‐759) 17	(6‐406) 15 (6‐118) 0.23
Myocardial infarction 4 5 0 0 0.66
Cerebrovascular accident 4 4 1 1 0.95
Anastomotic leak 15 34* 0 3 0.006*
Urinary tract infection 57 41 5 6 0.26
Intra‐abdominal abscess 29 35 4 5 0.84
Pancreatic infection 9 7 1 2 0.93
Viral systemic infection 4 8 3 1 0.13
Bacterial systemic 
infection
32 33 3 6 0.89
Fungal systemic infection 7 4 0 1 0.65
Pancreatitis 16 24 5 3 0.35
Episode of acute rejection 64 77 9 14 0.62
*,	highlights	significant	finding.
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difficult to account for without considering statistical methods of 
imputation which were not undertaken for this study.
An unusual finding from this study has been that men were more 
likely than women to receive pancreas grafts from “risky” donors 
with a history of alcohol abuse or drug misuse. This phenomenon 
is difficult to understand but may be the result of a subconscious 
gender bias. There have been previous studies that reported clini‐
cian's decisions regarding organ allocation and listing for transplant 
are subject to socioeconomic and racial bias25,26; however, there is 
very limited data about the effect of recipient's gender on these 
decisions.
Our findings are consistent with those of a previous, much 
smaller study, which found no impact of donor substance misuse 
on early pancreas graft failure.27	Whilst	this	is	reassuring,	the	other	
study was based on a single center experience, with a cohort of 62 
donors and no long‐term follow‐up. Having used data from the UK 
registry, our findings have greater statistical power, wider applicabil‐
ity, and the potential for greater clinical impact.
The majority of patients receiving a pancreas transplant had a 
simultaneous kidney transplant. However, our findings are contrary 
to those found in kidney transplants, with donor smoking having 
a significant effect on patient outcomes in kidney allografts.12 It is 
unclear why this difference exists; however, that study utilized the 
American	UNOS	registry	for	analysis	with	donors	from	prior	to	1999,	
whilst our study is a more contemporaneous UK registry analysis. 
Therefore, differences in the donor population groups may account 
for this discrepancy.
This study has been conducted using data from a large regis‐
try series, with long‐term follow‐up of 10 years. Consequently, it 
is very reassuring and convincing to see such positive outcomes. 
Decisions will still have to be taken on an organ‐by‐organ basis, 
weighing up risks and benefits for that particular recipient and 
collectively considering other donor factors. It is important that 
these decisions are taken during a process of shared decision mak‐
ing, with the patient fully informed of the risks and benefits of the 
individual grafts. Our study provides clinicians and surgeons with 
the ability to explain the evidence base regarding these allocation 
decisions and more confidence in the utility of this group of mar‐
ginal donors.
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